This HTML5 document contains 129 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n7http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q46432419
rdf:type
wikibase:Item
schema:description
2016年学术文章 2016年學術文章 מאמר מדעי wissenschaftlicher Artikel artigo científico artigo científico 2016년 논문 2016年学术文章 наукова стаття, опублікована в травні 2016 tudományos cikk videnskabelig artikel bài báo khoa học naučni članak vitskapeleg artikkel 2016年学术文章 مقالة علمية نشرت في 16 مايو 2016 wetenschappelijk artikel научна статия 2016年学术文章 scientific article published on 16 May 2016 научни чланак 2016年学术文章 artículu científicu 2016年學術文章 tieteellinen artikkeli vědecký článek мақолаи илмӣ scientific article published on 16 May 2016 บทความทางวิทยาศาสตร์ teaduslik artikkel scienca artikolo articolo scientifico artikulong pang-agham ১৬ মে ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vitenskapelig artikkel 2016年の論文 2016年學術文章 научни чланак bilimsel makale article scientifique article scientific vetenskaplig artikel 2016年學術文章 scientific article published on 16 May 2016 artículo científico publicado en 2016 article científic 2016 nî lūn-bûn artigo científico artikel ilmiah სამეცნიერო სტატია artikull shkencor vedecký článok artykuł naukowy научная статья επιστημονικό άρθρο 2016年学术文章 articol științific 2016年學術文章
p:P577
wds:Q46432419-3A5FC918-5DC5-46D4-A7D0-04CD10743F5D
wdt:P577
2016-05-16T00:00:00Z
p:P2860
wds:Q46432419-09F5F3A4-B12A-407E-BB63-245023DF791E wds:Q46432419-1022AFE5-0E70-4E73-80FF-2510A615A111 wds:Q46432419-19F1E0C6-3812-43A3-A45C-8734A78BD26A wds:Q46432419-3C5D82AE-20A5-4926-8550-AA3CB8D70355 wds:Q46432419-3D5FE584-01A4-454D-BADB-8DFD2E249B4A wds:Q46432419-3E8A62D5-89A7-4F5F-BFC6-7EA7A69D8DA7 wds:Q46432419-3FBD241A-1455-40CA-A722-3912633144BB wds:Q46432419-435B81A1-3310-4618-9E66-4A64F3BE803F wds:Q46432419-486FF539-0BF9-40E4-8482-2069B2AF5935 wds:Q46432419-48C97749-2A01-476D-B3DF-A6A0738C9790 wds:Q46432419-48DAA9C3-566D-46F1-A07C-FE8F0DA713B8 wds:Q46432419-4D59B2B4-41F6-4E7C-A660-EAE4D534AE54 wds:Q46432419-5460800B-C810-463B-BF77-3CEBE89B05D7 wds:Q46432419-64524B59-23C1-4422-82D2-CC0869DE3C77 wds:Q46432419-855B9E07-B4BB-40F3-B6DF-37357F5730BD wds:Q46432419-8C932984-61CC-45E9-AB0F-9EEF90F825FC wds:Q46432419-A7572E08-47F1-4724-A7E1-B5C6B7C022CF wds:Q46432419-B56B614A-D274-407F-AFCF-18F53663757A wds:Q46432419-C773877F-31DE-4440-8008-2BAC494042B8 wds:Q46432419-DFEAA1A1-1A53-47AC-B964-7F765BBC3D24
wdt:P2860
wd:Q36595290 wd:Q46253134 wd:Q37863988 wd:Q44918517 wd:Q42914716 wd:Q42272171 wd:Q27005966 wd:Q37718836 wd:Q35802414 wd:Q34549410 wd:Q37702687 wd:Q53127020 wd:Q38248293 wd:Q24685958 wd:Q37028556 wd:Q48025834 wd:Q34241661 wd:Q43253809 wd:Q28199347 wd:Q34592826
p:P2093
wds:Q46432419-F0A43090-6DC2-4EF9-8E4D-A24065F360D4 wds:Q46432419-2B2C3F0F-49E2-45CB-BEED-A44446287079
wdt:P2093
Amro M S El-Ghammaz Essam Abdelwahed
rdfs:label
Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis
skos:prefLabel
Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis
schema:name
Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis
p:P1476
wds:Q46432419-D5D11CC9-BBCC-483E-91E1-A2F3A18E1513
wdt:P1476
Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis
p:P304
wds:Q46432419-546775CF-4A33-416E-AE0A-9B9C6449B1A9
wdt:P304
1315-1321
p:P31
wds:Q46432419-DB11328A-60D2-4E46-897F-C43BA1BCD318
wdt:P31
wd:Q13442814
p:P698
wds:Q46432419-7BA951A8-EDA0-48A0-9769-A593C0446143
wdtn:P698
n11:27184486
wdt:P698
27184486
p:P1433
wds:Q46432419-1BDFA44A-A4B9-449F-A9D0-2CEEE43C59FD
wdt:P1433
wd:Q15766509
p:P433
wds:Q46432419-A58248C5-9AAD-49B7-BA40-5A8AB47DC2BB
p:P478
wds:Q46432419-2C90D360-8385-4601-BE60-AD783CE467C5
wdt:P433
8
wdt:P478
95
p:P356
wds:Q46432419-26791014-D2E0-4848-AFBD-D11FD2F76900
wdtn:P356
n7:S00277-016-2692-0
wdt:P356
10.1007/S00277-016-2692-0